← Compound index
COMPOUND RECORD / CHELOHART

ChelohartЧелохарт

A peptide mixture from calf or pig heart tissue, studied in heart-cell cultures and a small human exercise-test report.

Source linked

What the studies found

Lab research · 2015

[POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS].

Findings for this preparation

Chelohart was among the calf-tissue preparations tested in corresponding rat organotypic cultures. The abstract reports tissue-growth and marker changes across the preparations; it does not provide a separate numerical effect estimate for this preparation.

Study notes · methods, sources and limitations

Participants or model Organotypic tissue cultures from young and old rats

Important limitations

  • Tissue-culture growth is not organ regeneration in patients; equivalence to current branded products is unverified. Full methods, reporting completeness and independent replication remain to be appraised.

Advances in gerontology = Uspekhi gerontologii · PMID 26390619 · Original journal report

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2011

Chelohart: clinical report on a tissue-derived preparation

Angina during cycle ergometry
36.4% with Chelohart versus 50% with conventional care. Shared baseline 68.8%.The report marks p < 0.05 versus conventional care.
Achieving submaximal heart rate
54.5% versus 40%. Shared baseline 21.9%.The report marks p < 0.05 versus conventional care.
Threshold exercise power
119.3 ± 4.6 versus 115.2 ± 5.4 in the report’s stated units.The text reports a nonsignificant between-group difference.

Angina occurred during exercise testing in 36.4% with Chelohart and 50% with conventional care. Threshold exercise power did not differ significantly between groups.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 32 angina patients: 22 adjunctive Chelohart; 10 controls.

Design 22 adults received one Chelohart capsule twice daily with meals for 30 days alongside conventional care. Ten controls received conventional therapy alone.

Important limitations

  • A larger numerical improvement is not necessarily a significant between-group difference. Allocation, blinding and complete adverse-event collection need verification from original study documentation. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
  • The report leaves allocation and masking unspecified and gives a shared baseline for the exercise table.

Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date · Institute report — commercial reproduction

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗
01 / OVERVIEW

About Chelohart

Identity / background source ↗

Research background

Chelohart is a heart-derived peptide preparation. A 32-person Medical Center report measured exercise-test outcomes in people with angina.

Compound class
Tissue-derived peptide preparation
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

32 angina patients: 22 adjunctive Chelohart; 10 controls.

Study methods

Small comparative institute report; allocation, blinding and outcome interpretation require caution

Independent replication

New citations are not automatically independent replication; shared programs and translated reports require cohort checks

Source access

New indexed primary abstracts and/or report reproductions linked; review depth shown per source

Safety evidence

Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Lab research · 2015

[POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS].

Chelohart was among the calf-tissue preparations tested in corresponding rat organotypic cultures. The abstract reports tissue-growth and marker changes across the preparations; it does not provide a separate numerical effect estimate for this preparation.

Study notes and original source
2015In vitroEnglish abstract

[POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS].

· Original journal report

Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN · Advances in gerontology = Uspekhi gerontologii · PMID 26390619

Calf-tissue preparations, including Ventvil, stimulated corresponding tissue-culture growth with changes in proliferation-related markers.

Population / setting
Organotypic tissue cultures from young and old rats
Source reviewed
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
  • Tissue-culture growth is not organ regeneration in patients; equivalence to current branded products is unverified.
  • Full methods, reporting completeness and independent replication remain to be appraised.

Reviewed 2026-10-05.

Read the source ↗

Comparison in people · 2011

Chelohart: clinical report on a tissue-derived preparation

Angina occurred during exercise testing in 36.4% with Chelohart and 50% with conventional care. Threshold exercise power did not differ significantly between groups.

Angina during cycle ergometry · 36.4% with Chelohart versus 50% with conventional care. Shared baseline 68.8%. · The report marks p < 0.05 versus conventional care.

Study notes and original source
2011Human comparative studyFull text available

Chelohart: clinical report on a tissue-derived preparation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date

Angina occurred during exercise testing in 36.4% with Chelohart and 50% with conventional care. Threshold exercise power did not differ significantly between groups.

Results and tables

Reported findings and study design

22 adults received one Chelohart capsule twice daily with meals for 30 days alongside conventional care. Ten controls received conventional therapy alone.

Population or model 32 angina patients: 22 adjunctive Chelohart; 10 controls.

Results · Medical Center report, PDF pages 84–85, Table 3
MeasureResultComparison, timing and statistics
Angina during cycle ergometry36.4% with Chelohart versus 50% with conventional care. Shared baseline 68.8%.The report marks p < 0.05 versus conventional care.
Achieving submaximal heart rate54.5% versus 40%. Shared baseline 21.9%.The report marks p < 0.05 versus conventional care.
Threshold exercise power119.3 ± 4.6 versus 115.2 ± 5.4 in the report’s stated units.The text reports a nonsignificant between-group difference.

The report leaves allocation and masking unspecified and gives a shared baseline for the exercise table.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
32 angina patients: 22 adjunctive Chelohart; 10 controls.
Source reviewed
Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
  • A larger numerical improvement is not necessarily a significant between-group difference. Allocation, blinding and complete adverse-event collection need verification from original study documentation.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Reviewed 2026-11-16.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗